(:AXNX)
Business Focus: N/A
Nov 15, 2024 07:43 am ET
Boston Scientific Closes Acquisition of Axonics, Inc.
MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.
Nov 07, 2024 04:01 pm ET
Axonics Reports Third Quarter 2024 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2024.
Sep 26, 2024 06:00 am ET
Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia
Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder and fecal incontinence.
Sep 18, 2024 06:59 pm ET
Axonics Prevails in Patent Infringement Lawsuit with Medtronic
Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in U.S. District Court for the Central District of California.
Aug 01, 2024 04:01 pm ET
Axonics Reports Second Quarter 2024 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended June 30, 2024.
Apr 24, 2024 06:30 am ET
Boston Scientific Announces Results for First Quarter 2024
MARLBOROUGH, Mass., April 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $495 million or $0.33 per share (EPS), compared to $300 million or $0.21 per share a year ago, and achieved adjusted3 EPS of $0.56 for the period, compared to $0.47 a year ago.
Mar 22, 2024 04:01 pm ET
Axonics Stockholders Approve Merger Agreement with Boston Scientific
Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics’ merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shares of Axonics’ common stock outstanding and entitled to vote at the special meeting voted in favor of adopting the merger agreement. Final voting results, as tabulated by an independent inspector of election, will be reported on a Form 8-K to be filed with the U.S. Securities and Exchange Commission.
Mar 21, 2024 04:54 pm ET
Axonics Provides Update on Inter Partes Review Proceedings
Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting.
Mar 14, 2024 06:00 am ET
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval.
Mar 02, 2024 10:45 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates MDC, AXNX, CPE
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: M.D.C. Holdings, Inc. (NYSE: MDC)’s...
Mar 01, 2024 05:15 pm ET
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – KAMN, JNPR, INBX, AXNX
Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New...
Feb 29, 2024 04:01 pm ET
Axonics Responds to ITC Action by Medtronic
Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along with a parallel action in U.S. District Court for the District of Delaware. The complaint alleges that Axonics infringes two Medtronic patents that purportedly relate to a “patient programmer with automated MRI compatibility verification” for an implantable medical device.
Feb 28, 2024 04:01 pm ET
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2023.
Feb 28, 2024 12:00 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AXNX, KAMN, JNPR, AVRO
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Axonics, Inc. (NASDAQ: AXNX)’s sale to...
Feb 27, 2024 03:30 pm ET
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc. (NasdaqGS: AXNX) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Axonics will receive $71.00 in cash for each share of Axonics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Feb 26, 2024 06:50 pm ET
INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BATL, AVRO, AXNX, JNPR
NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating:
Feb 24, 2024 10:14 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AXNX, KAMN, BATL, JNPR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Axonics, Inc. (NASDAQ: AXNX)’s sale to...
Feb 23, 2024 05:06 pm ET
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – AXNX, JNPR, BATL, AVRO
Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New...
Feb 17, 2024 12:22 pm ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates PGTI, AXNX, AVRO, CTLT
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PGT Innovations, Inc. (NYSE: PGTI)’s...
Feb 16, 2024 10:40 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, AXNX, BATL, APA
NEW YORK, Feb. 16, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Feb 10, 2024 10:53 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AXNX, PGTI, EGLE, BBAI
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Axonics, Inc. (NASDAQ: AXNX)’s sale to...
Feb 06, 2024 09:32 am ET
INVESTIGATION ALERT: Halper Sadeh LLC Investigates AXNX, AMAM, FGH
NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 31, 2024 05:30 am ET
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or $0.34 per share (EPS), compared to $126 million or $0.09 per share a year ago and achieved adjusted3 EPS of $0.55 for the period, compared to $0.45 a year ago.
Jan 29, 2024 10:02 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates RYZB, FGH, AXNX, AMAM
NEW YORK, Jan. 29, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 26, 2024 10:18 pm ET
AXONICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
NEW ORLEANS, Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Axonics, Inc. (NasdaqGS: AXNX) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Axonics will receive $71.00 in cash for each share of Axonics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jan 25, 2024 08:07 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates VIA, FGH, AXNX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Via Renewables, Inc. (NASDAQ: VIA)’s...
Jan 24, 2024 05:17 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – MDC, HARP, CVLY, AXNX
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and...
Jan 23, 2024 01:45 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates FGH, AMAM, AXNX
NEW YORK, Jan. 23, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 19, 2024 08:00 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – GRCL, AXNX, HARP, CVLY
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered...
Jan 17, 2024 12:00 am ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates FGH, AXNX, AMAM, HARP
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: FG Group Holdings Inc. (NYSE:...
Jan 16, 2024 10:00 am ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates AMAM, AXNX, HARP, GRCL
NEW YORK, Jan. 16, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 16, 2024 08:05 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AX
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jan 13, 2024 08:47 am ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates FGH, AXNX, HARP, AMAM
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: FG Group Holdings Inc. (NYSE:...
Jan 12, 2024 07:20 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger - GRCL, KRTX, AXNX, HA
NEW YORK, Jan. 12, 2024 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Jan 10, 2024 05:10 pm ET
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc. (NasdaqGS: AXNX) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Axonics will receive $71.00 in cash for each share of Axonics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jan 10, 2024 02:07 pm ET
Kuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law Firm
NEW YORK, Jan. 10, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
Jan 09, 2024 05:31 pm ET
ALERT: Juan Monteverde Encourages the Shareholders of AXNX, BVH, GRCL, CVLY to Take Action
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered...
Jan 08, 2024 08:21 pm ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates HARP, AMAM, AXNX, EAR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Harpoon Therapeutics, Inc. (NASDAQ:...
Jan 08, 2024 05:31 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AX
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jan 08, 2024 03:55 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Axonics, Inc.
NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Axonics, Inc. (NASDAQ: AXNX) and its board of directors concerning the proposed acquisition of the company by Boston Scientific Corporation (NYSE: BSX). Stockholders will receive $71.00 for each share of Axonics stock that they hold. The transaction is valued at approximately $3.7 billion and is expected to close in the first half of 2024.
Jan 08, 2024 10:36 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HARP, AMAM, AXNX
NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 08, 2024 09:57 am ET
Shareholder Alert: Ademi LLP investigates whether Axonics, Inc. has obtained a Fair Price in its transaction with Boston Scientific
MILWAUKEE, Jan. 8, 2024 /PRNewswire/ -- Ademi LLP is investigating Axonics (Nasdaq: AXNX) for possible breaches of fiduciary duty and other violations of law in its transaction with Boston Scientific.
Jan 08, 2024 08:47 am ET
AXNX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Axonics to Boston Scientific
The law firm of Wohl & Fruchter LLP is investigating the fairness of the $71.00 per share in cash pursuant to which Axonics, Inc. (Nasdaq: AXNX) (“Axonics”) has agreed to be sold to Boston Scientific Corporation (“Boston Scientific”). The sales...
Jan 08, 2024 08:20 am ET
AXNX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Axonics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Axonics, Inc. (NASDAQ: AXNX) to Boston Scientific Corporation for $71.00 in cash per share is fair to Axonics shareholders.
Jan 08, 2024 07:00 am ET
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion.
Jan 08, 2024 07:00 am ET
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023.
Jan 08, 2024 06:00 am ET
Boston Scientific Announces Agreement to Acquire Axonics, Inc.
Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction
Dec 27, 2023 04:01 pm ET
Axonics to Present at the J.P. Morgan Healthcare Conference
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan Healthcare conference at 5:15 p.m. Pacific Time on Monday, January 8, 2024.
Nov 06, 2023 12:00 pm ET
Revolutionizing Care: NeuroQure’s Groundbreaking Path to Treating Genetic Intellectual Disabilities
NeuroQure has embarked on a transformative journey aimed at revolutionizing the treatment landscape for Fragile X Syndrome and Autism Spectrum Disorder (ASD). With an unwavering commitment to addressing the monogenic origins of these conditions,...
Nov 01, 2023 06:00 am ET
Axonics to Participate in November Investor Conferences
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in November:
Oct 30, 2023 04:01 pm ET
Axonics Reports Third Quarter 2023 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2023.
Oct 02, 2023 06:00 am ET
Axonics to Report Third Quarter 2023 Financial Results on October 30
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report third quarter 2023 financial results after the close of trading on Monday, October 30.
Aug 25, 2023 06:00 am ET
Axonics to Participate in September Investor Conferences
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in September:
Aug 21, 2023 06:00 am ET
Axonics Announces CFO Retirement and Appoints Successor
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. Dearen, president and chief financial officer, is retiring from the company. Kari Keese, vice president of finance and accounting, will succeed Mr. Dearen on Monday, October 2.
Jul 27, 2023 04:01 pm ET
Axonics Reports Second Quarter 2023 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended June 30, 2023.
Jun 29, 2023 06:00 am ET
Axonics to Report Second Quarter 2023 Financial Results on July 27
Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the conference call by telephone, interested parties may register at the following link: Axonics 2Q23 registration.
May 01, 2023 04:01 pm ET
Axonics Reports First Quarter 2023 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2023.
Apr 25, 2023 06:00 am ET
Axonics to Participate in Upcoming Investor Conferences
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following upcoming investor conferences:
Apr 24, 2023 06:00 am ET
Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the acquisition of a lead placement solution from Radian, LLC that complements Axonics’ existing sacral neuromodulation (SNM) offering.
Apr 10, 2023 06:00 am ET
Axonics to Report First Quarter 2023 Financial Results on May 1
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report first quarter 2023 financial results after the close of trading on Monday, May 1.
Mar 29, 2023 06:00 am ET
Axonics Ranked No. 2 on the Financial Times 2023 List of the Fastest Growing Companies in the Americas
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 2 on the Financial Times 2023 list of the fastest growing companies in the Americas. This follows the company’s No.
Mar 07, 2023 06:00 am ET
Axonics to Participate in the SUFU 2023 Winter Meeting
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is participating as a platinum sponsor of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2023 Winter Meeting, which is being held in Nashville from March 7-11.
Mar 01, 2023 04:01 pm ET
Axonics Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2022.
Feb 08, 2023 04:30 pm ET
Axonics to Report Fourth Quarter 2022 Financial Results on March 1
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter 2022 financial results after the close of trading on Wednesday, March 1.
Jan 31, 2023 06:00 am ET
Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration has approved the company’s fourth-generation rechargeable sacral neuromodulation system.
Jan 11, 2023 06:00 am ET
Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fiscal year ended December 31, 2022 and issued fiscal year 2023 revenue guidance.
Dec 21, 2022 06:00 am ET
Axonics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Dec 13, 2022 06:00 am ET
Axonics Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Health Canada has approved the company’s fourth-generation rechargeable sacral neuromodulation system.
Nov 18, 2022 06:00 am ET
Axonics® to Participate in the Piper Sandler Healthcare Conference
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the Piper Sandler Healthcare Conference on December 1, 2022.
Nov 16, 2022 11:06 am ET
Axonics® Ranked No. 4 on the 2022 Deloitte Technology Fast 500™ List of the Fastest Growing Companies in North America
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 4 on the Deloitte Technology Fast 500, a
Oct 31, 2022 04:01 pm ET
Axonics® Reports Third Quarter 2022 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2022.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.